Kestra Medical Technologies, LTD 8-K filings

Kestra Medical Technologies, Ltd. announced a new $200 million senior secured term loan facility, alongside reporting strong Q4 and FY26 financial results with significant revenue and gross margin growth.

Kestra Medical Technologies announced robust third-quarter fiscal 2026 financial results, exceeding revenue guidance and expanding gross margins.

Kestra Medical Technologies announced robust second-quarter fiscal 2026 financial results, featuring significant revenue growth and expanded gross margins, alongside an upward revision of its full-year revenue guidance.

Kestra Medical Technologies, Ltd. successfully closed an underwritten public offering, raising approximately $148.4 million in net proceeds through the sale of 6.9 million common shares at $23.00 each.

Kestra Medical Technologies announced preliminary second quarter fiscal 2026 results, projecting over 50% revenue growth and improved gross margins.

Kestra Medical Technologies announced primary results from its ACE-PAS study, confirming the strong safety and 100% effectiveness of its ASSURE Wearable Cardioverter Defibrillator.

Kestra Medical Technologies announced robust first quarter fiscal 2026 results, exceeding revenue expectations and expanding gross margins.

Kestra Medical Technologies shareholders approved all proposals at their 2025 annual meeting, including director elections and a new employee stock purchase plan.

Kestra Medical Technologies announced robust financial results for the fourth quarter and fiscal year 2025, showcasing significant revenue growth and gross margin expansion fueled by accelerating demand for its cardiac recovery system.

Kestra Medical Technologies, Ltd. announced the appointment of seasoned medical technology executive Conor Hanley to its Board of Directors and updated the employment agreements for its top executives to clarify 'Good Reason' termination clauses.

Kestra Medical Technologies announces strong Q3 fiscal 2025 results, highlighted by an 82% revenue increase and significant gross margin improvement, following its recent IPO.

Kestra Medical Technologies finalizes agreements related to its initial public offering, including warrant issuances and adoption of an omnibus incentive plan.